- Home
- DNN vs ETNB Comparison
DNN vs ETNB Comparison
Compare DNN & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNN
- ETNB
- Stock Information
- Founded
- DNN 1936
- ETNB 2018
- Country
- DNN Canada
- ETNB United States
- Employees
- DNN N/A
- ETNB N/A
- Industry
- DNN Other Metals and Minerals
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- DNN Basic Materials
- ETNB Health Care
- Exchange
- DNN Nasdaq
- ETNB Nasdaq
- Market Cap
- DNN 1.3B
- ETNB 1.5B
- IPO Year
- DNN 1997
- ETNB 2019
- Fundamental
- Price
- DNN $1.81
- ETNB $10.10
- Analyst Decision
- DNN Strong Buy
- ETNB Strong Buy
- Analyst Count
- DNN 2
- ETNB 8
- Target Price
- DNN $3.00
- ETNB $26.43
- AVG Volume (30 Days)
- DNN 169.6M
- ETNB 2.2M
- Earning Date
- DNN 08-07-2025
- ETNB 08-04-2025
- Dividend Yield
- DNN N/A
- ETNB N/A
- EPS Growth
- DNN N/A
- ETNB N/A
- EPS
- DNN N/A
- ETNB N/A
- Revenue
- DNN $3,176,679.00
- ETNB N/A
- Revenue This Year
- DNN $288.69
- ETNB N/A
- Revenue Next Year
- DNN $22.40
- ETNB N/A
- P/E Ratio
- DNN N/A
- ETNB N/A
- Revenue Growth
- DNN 24.45
- ETNB N/A
- 52 Week Low
- DNN $1.08
- ETNB $4.16
- 52 Week High
- DNN $2.47
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- DNN 56.90
- ETNB 57.46
- Support Level
- DNN $1.73
- ETNB $9.45
- Resistance Level
- DNN $1.88
- ETNB $10.20
- Average True Range (ATR)
- DNN 0.10
- ETNB 0.54
- MACD
- DNN -0.00
- ETNB -0.09
- Stochastic Oscillator
- DNN 71.21
- ETNB 64.96
About DNN Denison Mines Corp (Canada)
Denison Mines Corp is a uranium exploration and development company focused on the Athabasca Basin region of northern Saskatchewan, Canada. The company holds a noteworthy 95% interest in its flagship Wheeler River Uranium Project, the undeveloped uranium project located in the infrastructure-rich eastern part of the Athabasca Basin. Additionally, it is involved in mine decommissioning and environmental services through its Closed Mines group, which manages the Elliot Lake reclamation projects and offers third-party post-closure mine care and maintenance services. The Company operates in two main segments: the Mining segment and the Corporate and Other segment. The majority of revenue is generated from the mining segment.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).